Harnessing emerging paradigms in chemical engineering to accelerate the development of pharmaceutical products

[1]  J. Katz,et al.  Facts vs Fiction: the Role of Cannabinoids in the Treatment of Glaucoma , 2019, Current Ophthalmology Reports.

[2]  Vikramaditya G. Yadav,et al.  A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery , 2018, Drug Delivery and Translational Research.

[3]  Asher Mullard.  2017 FDA drug approvals , 2018, Nature Reviews Drug Discovery.

[4]  Asher Mullard,et al.  2016 FDA drug approvals , 2017, Nature Reviews Drug Discovery.

[5]  Roger A. Sheldon,et al.  The E factor 25 years on: the rise of green chemistry and sustainability , 2017 .

[6]  M. Cecchini,et al.  Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease , 2016, Scientific Reports.

[7]  Hu Li,et al.  A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes , 2016, Scientific Reports.

[8]  P. Mitchell,et al.  Assessment of polygenic effects links primary open-angle glaucoma and age-related macular degeneration , 2016, Scientific Reports.

[9]  Li Ye,et al.  The Traditional Medicine and Modern Medicine from Natural Products , 2016, Molecules.

[10]  D. Newman,et al.  Natural Products as Sources of New Drugs from 1981 to 2014. , 2016, Journal of natural products.

[11]  D. Dias,et al.  The pharmaceutical industry and natural products: historical status and new trends , 2015, Phytochemistry Reviews.

[12]  Roger A. Sheldon,et al.  Overcoming barriers to green chemistry in the pharmaceutical industry – the Green Aspiration Level™ concept , 2015 .

[13]  Asher Mullard.  2014 FDA drug approvals , 2015, Nature Reviews Drug Discovery.

[14]  A. Harvey,et al.  The re-emergence of natural products for drug discovery in the genomics era , 2015, Nature Reviews Drug Discovery.

[15]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[16]  Vikramaditya G. Yadav,et al.  Metabolic engineering: the ultimate paradigm for continuous pharmaceutical manufacturing. , 2014, ChemSusChem.

[17]  Vikramaditya G. Yadav.  Biosynthonics: Charting the Future Role of Biocatalysis and Metabolic Engineering in Drug Discovery , 2014 .

[18]  David J Newman,et al.  Natural products: a continuing source of novel drug leads. , 2013, Biochimica et biophysica acta.

[19]  S. Majumdar,et al.  Effect of ion pairing on in vitro transcorneal permeability of a Δ(9) -tetrahydrocannabinol prodrug: potential in glaucoma therapy. , 2012, Journal of pharmaceutical sciences.

[20]  Asher Mullard,et al.  2011 FDA drug approvals , 2012, Nature Reviews Drug Discovery.

[21]  Wayne Mitchell.  Natural products from synthetic biology. , 2011, Current opinion in chemical biology.

[22]  S. Majumdar,et al.  Enhanced Solubility, Stability, and Transcorneal Permeability of Delta-8-Tetrahydrocannabinol in the Presence of Cyclodextrins , 2011, AAPS PharmSciTech.

[23]  Rainer Breitling,et al.  Exploiting plug-and-play synthetic biology for drug discovery and production in microorganisms , 2011, Nature Reviews Microbiology.

[24]  Ricardo Macarron,et al.  Enhancements of screening collections to address areas of unmet medical need: an industry perspective. , 2010, Current opinion in chemical biology.

[25]  Hong-yu Zhang,et al.  Natural products and drug discovery , 2009, EMBO reports.

[26]  D. Sinclair,et al.  Xenohormesis: Sensing the Chemical Cues of Other Species , 2008, Cell.

[27]  Sorel Muresan,et al.  Developing a drug-like natural product library. , 2008, Journal of natural products.

[28]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[29]  H. Quigley,et al.  The number of people with glaucoma worldwide in 2010 and 2020 , 2006, British Journal of Ophthalmology.

[30]  F. Koehn,et al.  The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.

[31]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[32]  S. Rossi,et al.  Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcine buccal and vaginal tissue, Caco‐2 cell lines, and rat jejunum , 2004, The Journal of pharmacy and pharmacology.

[33]  R. Pertwee,et al.  Cannabinoids and glaucoma , 2004, British Journal of Ophthalmology.

[34]  M. Rawlins.  Cutting the cost of drug development? , 2004, Nature Reviews Drug Discovery.

[35]  S. Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[36]  Hans-Jürgen Federsel,et al.  A guide to drug discovery: Logistics of process R&D: transforming laboratory methods to manufacturing scale , 2003, Nature Reviews Drug Discovery.

[37]  Peter McCourt,et al.  Hormone evolution: The key to signalling , 2003, Nature.

[38]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[39]  G. Schneider,et al.  Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.

[40]  G. Gessa,et al.  The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies , 2001, The European journal of neuroscience.

[41]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[42]  Loftssona,et al.  Cyclodextrins in ophthalmic drug delivery. , 1999, Advanced drug delivery reviews.

[43]  Shulin Ding.  RECENT DEVELOPMENTS IN OPHTHALMIC DRUG DELIVERY , 1998 .

[44]  K. Green,et al.  Multiple-Drop Study of Topically Applied 1% Δ9-Tetrahydrocannabinol in Human Eyes , 1983 .

[45]  Hyun Uk Kim,et al.  Metabolic engineering of microorganisms: general strategies and drug production. , 2009, Drug discovery today.

[46]  Fred Hendrikse,et al.  Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. , 2005, Ophthalmology.

[47]  Carole-Anne Slowey,et al.  Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. , 2000, The Journal of pharmacology and experimental therapeutics.

[48]  J. C. Keister,et al.  Limits on optimizing ocular drug delivery. , 1991, Journal of pharmaceutical sciences.